A standard CD34+/CD117+/CD13+/CD33+ AML phenotype does not lend itself to the monitoring of MRD, since this is also the phenotype of normal bone marrow (BM) hematopoietic stem cells (HSCs). The gene discussed is CD34; the disease is acute myeloid leukemia.